 Home > Biochemistry News > Biotechnology News > Bicyclic peptide accurately delivers cytotoxic drugs to treat bladder cancer and ovarian cancer, clinical results are positive

Bicyclic peptide accurately delivers cytotoxic drugs to treat bladder cancer and ovarian cancer, clinical results are positive

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

cell signaling antibodies

ovarian stromal tumor

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bicycle Therapeutics today announced that two new-generation bicyclic peptide-conjugated toxins have shown positive anti-cancer activity in phase 1 clinical trials

Bicycle company uses bicyclic peptide technology (named Bicycle) to develop differentiated therapies

BT5528 is a bicyclic peptide-conjugated toxin targeting EphA2

▲Introduction to BT5528 (picture source: Bicycle Therapeutics official website)

In this phase 1 clinical trial, cancer patients who had received multiple pre-treatments (median number of treatments were 7) received BT5528 treatment

Two patients with urothelial cancer received treatment, and they both achieved partial remission

Eight patients with ovarian cancer received treatment, of which five patients were confirmed to be EphA2 positive by immunohistochemical tests

The company's BT8009 is a bicyclic peptide-conjugated toxin targeting Nectin-4

▲Tumor changes in patients treated with BT8009 (picture source: Bicycle Therapeutics official website)

▲Immuno-oncology therapy based on bicyclic peptides (picture source: Bicycle Therapeutics official website)

In addition to coupled toxins, the company's R&D pipeline also includes bispecific bicyclic peptide molecules that can simultaneously bind to tumor antigens and CD137, and they are expected to become a new generation of immuno-oncology therapies

Reference materials:

[1] Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express bicyclic peptides accurately deliver cytotoxic drugs and treat bladder cancer and ovarian cancer with positive clinical results

10-22

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Bicyclic peptide accurately delivers cytotoxic drugs to treat bladder cancer and ovarian cancer, clinical results are positive

Related Articles

Express bicyclic peptides accurately deliver cytotoxic drugs and treat bladder cancer and ovarian cancer with positive clinical results